Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

NIBIT-MESO-1: limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study.

Bironzo P, Taulli R.

J Thorac Dis. 2018 Nov;10(Suppl 33):S3878-S3881. doi: 10.21037/jtd.2018.09.135. No abstract available.

2.

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.

Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R.

Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.

3.

Tumor suppressors revival in CLL.

Carrà G, Taulli R, Morotti A.

Aging (Albany NY). 2017 Jun 26;9(6):1473-1474. doi: 10.18632/aging.101258. No abstract available.

4.

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.

Carrà G, Panuzzo C, Torti D, Parvis G, Crivellaro S, Familiari U, Volante M, Morena D, Lingua MF, Brancaccio M, Guerrasio A, Pandolfi PP, Saglio G, Taulli R, Morotti A.

Oncotarget. 2017 May 30;8(22):35508-35522. doi: 10.18632/oncotarget.16348.

5.

Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex.

Carrà G, Crivellaro S, Taulli R, Guerrasio A, Saglio G, Morotti A.

Int J Mol Sci. 2016 Nov 29;17(12). pii: E1997. Review.

6.

The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia.

Carrà G, Panuzzo C, Crivellaro S, Morena D, Taulli R, Guerrasio A, Saglio G, Morotti A.

Oncol Lett. 2016 Nov;12(5):3123-3126. Epub 2016 Sep 1.

7.

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.

Noguera NI, Piredda ML, Taulli R, Catalano G, Angelini G, Gaur G, Nervi C, Voso MT, Lunardi A, Pandolfi PP, Lo-Coco F.

Oncotarget. 2016 Oct 11;7(41):66386-66397. doi: 10.18632/oncotarget.11964.

8.

Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma.

Bersani F, Lingua MF, Morena D, Foglizzo V, Miretti S, Lanzetti L, Carrà G, Morotti A, Ala U, Provero P, Chiarle R, Singer S, Ladanyi M, Tuschl T, Ponzetto C, Taulli R.

Cancer Res. 2016 Oct 15;76(20):6095-6106. Epub 2016 Aug 28.

9.

The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.

Carrà G, Torti D, Crivellaro S, Panuzzo C, Taulli R, Cilloni D, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2016 Oct 4;7(40):66287-66298. doi: 10.18632/oncotarget.11507. Review.

10.

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.

Morotti A, Torti D, Carra G, Panuzzo C, Crivellaro S, Taulli R, Fava C, Guerrasio A, Saglio G.

Curr Drug Targets. 2017;18(4):389-395. doi: 10.2174/1389450117666160608120527. Review.

PMID:
27291926
11.

The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.

Crivellaro S, Carrà G, Panuzzo C, Taulli R, Guerrasio A, Saglio G, Morotti A.

BMC Cancer. 2016 May 16;16:314. doi: 10.1186/s12885-016-2346-6. Review.

12.

Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.

Morena D, Maestro N, Bersani F, Forni PE, Lingua MF, Foglizzo V, Šćepanović P, Miretti S, Morotti A, Shern JF, Khan J, Ala U, Provero P, Sala V, Crepaldi T, Gasparini P, Casanova M, Ferrari A, Sozzi G, Chiarle R, Ponzetto C, Taulli R.

Elife. 2016 Mar 17;5. pii: e12116. doi: 10.7554/eLife.12116.

13.

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.

Morotti A, Carrà G, Panuzzo C, Crivellaro S, Taulli R, Guerrasio A, Saglio G.

Adv Hematol. 2015;2015:612567. doi: 10.1155/2015/612567. Epub 2015 Dec 30. Review.

14.

Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.

Crivellaro S, Panuzzo C, Carrà G, Volpengo A, Crasto F, Gottardi E, Familiari U, Papotti M, Torti D, Piazza R, Redaelli S, Taulli R, Guerrasio A, Saglio G, Morotti A.

Oncotarget. 2015 Sep 22;6(28):25217-25. doi: 10.18632/oncotarget.4611.

15.

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, Pandolfi PP.

Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.

16.

SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.

Coda DM, Lingua MF, Morena D, Foglizzo V, Bersani F, Ala U, Ponzetto C, Taulli R.

Cell Cycle. 2015;14(9):1389-402. doi: 10.1080/15384101.2015.1005993.

17.

A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells.

Guarnerio J, Riccardi L, Taulli R, Maeda T, Wang G, Hobbs RM, Song MS, Sportoletti P, Bernardi R, Bronson RT, Castillo-Martin M, Cordon-Cardo C, Lunardi A, Pandolfi PP.

Cancer Discov. 2015 Apr;5(4):396-409. doi: 10.1158/2159-8290.CD-14-1022. Epub 2015 Jan 22.

18.

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.

Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, Straley K, Karnik R, Meissner A, Small D, Su SM, Yen K, Zhang J, Pandolfi PP.

Cell Stem Cell. 2014 Mar 6;14(3):329-41. doi: 10.1016/j.stem.2013.12.016. Epub 2014 Jan 16.

19.

STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Spaccarotella E, Pellegrino E, Ferracin M, Ferreri C, Cuccuru G, Liu C, Iqbal J, Cantarella D, Taulli R, Provero P, Di Cunto F, Medico E, Negrini M, Chan WC, Inghirami G, Piva R.

Haematologica. 2014 Jan;99(1):116-24. doi: 10.3324/haematol.2013.088286. Epub 2013 Aug 23.

20.

Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma.

Taulli R, Foglizzo V, Morena D, Coda DM, Ala U, Bersani F, Maestro N, Ponzetto C.

Oncogene. 2014 May 1;33(18):2354-62. doi: 10.1038/onc.2013.188. Epub 2013 Jun 3.

PMID:
23728344
21.

Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):739-746. doi: 10.1038/ng.2654. Epub 2013 Jun 2.

22.

From pseudo-ceRNAs to circ-ceRNAs: a tale of cross-talk and competition.

Taulli R, Loretelli C, Pandolfi PP.

Nat Struct Mol Biol. 2013 May;20(5):541-3. doi: 10.1038/nsmb.2580. No abstract available.

23.

Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments.

Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, Léopold V, Tay Y, Provero P, Zecchina R, Pandolfi PP.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7154-9. doi: 10.1073/pnas.1222509110. Epub 2013 Mar 27.

24.

"Snorkeling" for missing players in cancer.

Taulli R, Pandolfi PP.

J Clin Invest. 2012 Aug;122(8):2765-8. doi: 10.1172/JCI63549. Epub 2012 Jul 2.

25.

Differential expression of microRNA-206 in skeletal muscle of female Piedmontese and Friesian cattle.

Miretti S, Martignani E, Taulli R, Bersani F, Accornero P, Baratta M.

Vet J. 2011 Dec;190(3):412-3. doi: 10.1016/j.tvjl.2010.12.012. Epub 2011 Feb 3.

26.

Micro-orchestrating differentiation in cancer.

Taulli R, Bersani F, Ponzetto C.

Cell Cycle. 2010 Mar 1;9(5):918-22. Epub 2010 Mar 7.

PMID:
20160508
27.

Amplification failure of the amelogenin gene (AMELX) caused by a primer binding site mutation.

Caratti S, Voglino G, Cirigliano V, Ghidini A, Taulli R, Torre C, Robino C.

Prenat Diagn. 2009 Dec;29(12):1180-2. doi: 10.1002/pd.2389. No abstract available.

PMID:
19842109
28.

The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C.

J Clin Invest. 2009 Aug;119(8):2366-78. doi: 10.1172/JCI38075. Epub 2009 Jul 20.

29.

An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.

Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastrù W, Christensen JG, Crepaldi T, Ponzetto C.

Clin Cancer Res. 2008 Apr 1;14(7):2220-6. doi: 10.1158/1078-0432.CCR-07-2064.

30.

A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging.

Miretti S, Roato I, Taulli R, Ponzetto C, Cilli M, Olivero M, Di Renzo MF, Godio L, Albini A, Buracco P, Ferracini R.

PLoS One. 2008 Mar 19;3(3):e1828. doi: 10.1371/journal.pone.0001828.

31.

Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.

Bersani F, Taulli R, Accornero P, Morotti A, Miretti S, Crepaldi T, Ponzetto C.

Eur J Cancer. 2008 Apr;44(6):876-84. doi: 10.1016/j.ejca.2008.02.022. Epub 2008 Mar 14.

PMID:
18342500
32.

The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes.

Scuoppo C, Riess I, Schmitt-Ney M, Allegra P, Forni PE, Bersani F, Taulli R, Accornero P, Crepaldi T, Ponzetto C.

Exp Cell Res. 2007 Jul 1;313(11):2308-17. Epub 2007 Apr 14.

PMID:
17490646
33.

Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells.

Filigheddu N, Gnocchi VF, Coscia M, Cappelli M, Porporato PE, Taulli R, Traini S, Baldanzi G, Chianale F, Cutrupi S, Arnoletti E, Ghè C, Fubini A, Surico N, Sinigaglia F, Ponzetto C, Muccioli G, Crepaldi T, Graziani A.

Mol Biol Cell. 2007 Mar;18(3):986-94. Epub 2007 Jan 3.

34.

Conditional activation of MET in differentiated skeletal muscle induces atrophy.

Crepaldi T, Bersani F, Scuoppo C, Accornero P, Prunotto C, Taulli R, Forni PE, Leo C, Chiarle R, Griffiths J, Glass DJ, Ponzetto C.

J Biol Chem. 2007 Mar 2;282(9):6812-22. Epub 2006 Dec 27.

35.

Leptin enhances STAT-3 phosphorylation in HC11 cell line: effect on cell differentiation and cell viability.

Motta M, Accornero P, Taulli R, Bernabei P, Desrivières S, Baratta M.

Mol Cell Endocrinol. 2007 Jan 15;263(1-2):149-55. Epub 2006 Oct 30.

PMID:
17070988
36.

High levels of Cre expression in neuronal progenitors cause defects in brain development leading to microencephaly and hydrocephaly.

Forni PE, Scuoppo C, Imayoshi I, Taulli R, Dastrù W, Sala V, Betz UA, Muzzi P, Martinuzzi D, Vercelli AE, Kageyama R, Ponzetto C.

J Neurosci. 2006 Sep 13;26(37):9593-602.

37.

NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line.

Morotti A, Cilloni D, Pautasso M, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Taulli R, Bracco E, Rege-Cambrin G, Gottardi E, Saglio G.

Am J Hematol. 2006 Dec;81(12):938-45.

38.

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C.

Cancer Res. 2006 May 1;66(9):4742-9.

39.

Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.

Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Pilatrino C, Guerrasio A, Taulli R, Bracco E, Pautasso M, Baraban D, Gottardi E, Saglio G.

Cancer. 2006 Mar 1;106(5):1188-96.

40.

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G.

Blood. 2006 Jan 15;107(2):689-97. Epub 2005 Sep 27.

41.

RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.

Taulli R, Accornero P, Follenzi A, Mangano T, Morotti A, Scuoppo C, Forni PE, Bersani F, Crepaldi T, Chiarle R, Naldini L, Ponzetto C.

Cancer Gene Ther. 2005 May;12(5):456-63.

PMID:
15719029
42.

Supplemental Content

Loading ...
Support Center